RenovoRx Inc (RNXT NASDAQ) stock market data APIs
$1.3489
-0.04(-3%)
as of July 10, 2025
Try our APIs with
free plan!
RenovoRx Inc Financial Data Overview
Price chart is built with
Anychart
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Prev. Close
1.3489
Open
1.3088
High
1.3687
Low
1.3088
52 wk Range
0.75-1.6899
Market Cap
48 092 K
Shares Outstanding
36 572 K
Revenue
240 K
EPS
-0.11
Beta
1.321
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get RenovoRx Inc data using free add-ons & libraries
Get RenovoRx Inc Fundamental Data
RenovoRx Inc Fundamental data includes:
- Net Revenue: 240 K
- EBITDA: -11 390 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-01
- EPS/Forecast: -0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RenovoRx Inc News
New
Kemira Q1 2025 presentation: Solid profitability maintained amid softer market
Introduction & Market Context Finnish chemicals company Kemira reported its first quarter 2025 results on April 25, demonstrating resilience in a challenging market environment. Despite facing increa...
RenovoRx shareholders elect directors and approve incentive plan amendments
RenovoRx , Inc. (NASDAQ:RNXT) announced the results of its 2025 annual meeting of stockholders held Tuesday. According to a press release statement based on the company’s SEC filing, shareholders vo...
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares. This adjustment follows the company'...
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. TAMP is expected to enable localized, targeted delivery of CF33 to ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
